Advertisement

CardioVascular and Interventional Radiology

, Volume 42, Issue 2, pp 276–282 | Cite as

Predictors of Recurrent Biliary Obstruction Following Percutaneous Uncovered Metal Stent Insertion in Patients with Distal Malignant Biliary Obstruction: An Analysis Using a Competing Risk Model

  • Jin-Xing Zhang
  • Bin Wang
  • Sheng Liu
  • Qing-Quan ZuEmail author
  • Hai-Bin ShiEmail author
Clinical Investigation Biliary
  • 89 Downloads
Part of the following topical collections:
  1. Biliary

Abstract

Objective

To evaluate predictive factors of recurrent biliary obstruction (RBO) following percutaneous uncovered metal stent placement for unresectable distal malignant biliary obstruction (MBO) by using a competing risk model.

Materials and Methods

Between March 2012 and March 2016, 119 patients underwent percutaneous uncovered metal stent placement with distal MBO at our institution. Univariate and multivariate analyses were conducted to identify the prognostic factors for RBO using a competing risk model.

Results

The median overall survival period was 170 days (range 19–775 days). Recurrent biliary obstruction before death was observed in 34 patients (28.6%). The 3-, 6-, and 12-month cumulative incidences of RBO were 14.3%, 21.0%, and 27.7%, respectively. A multivariate analysis indicated that ampullary carcinoma compared with metastatic carcinoma (hazard ratio [HR] = 4.86; 95% confidence interval [CI], 1.74–13.54; P = 0.003) and a stent insertion above the sphincter of Oddi (HR 2.49; 95% CI, 1.11–5.62; P = 0.028) were the independent risk factors for RBO when we considered death to be a competing risk.

Conclusion

Ampullary carcinoma and stent insertion above the sphincter of Oddi were risk factors for RBO in these patients who received percutaneous transhepatic stent placement.

Keywords

Biliary tract neoplasms Jaundice, Obstructive Self-expandable metallic stents Recurrence Regression analysis 

Notes

Acknowledgements

We would like to thank Jin LIU, MD, from the First Affiliated Hospital with Nanjing Medical University for his statistical work.

Compliance with Ethical Standards

Conflict of interest

No conflict of interest to declare.

Ethical Approval

Study protocol followed the guidelines of the World Medical Association Declaration of Helsinki and was approved by the Ethics Committee of our institution (Ethical review no. 2017-SR-307). For this retrospective study, formal consent was not required.

References

  1. 1.
    Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145:1215–29.CrossRefGoogle Scholar
  2. 2.
    Zhu HD, Guo JH, Zhu GY, et al. A novel biliary stent loaded with (125)I seeds in patients with malignant biliary obstruction: preliminary results versus a conventional biliary stent. J Hepatol. 2012;56:1104–11.CrossRefGoogle Scholar
  3. 3.
    Almadi MA, Barkun A, Martel M. Plastic vs. self-expandable metal stents for palliation in malignant biliary obstruction: a series of meta-analyses. Am J Gastroenterol. 2017;112:260–73.CrossRefGoogle Scholar
  4. 4.
    İNal M, Akgül E, Aksungur E, et al. Percutaneous self-expandable uncovered metallic stents in malignant biliary obstruction. Acta Radiol. 2015;44:139–46.Google Scholar
  5. 5.
    Tapping CR, Byass OR, Cast JE, et al. Percutaneous transhepatic biliary drainage (PTBD) with or without stenting-complications, re-stent rate and a new risk stratification score. Eur Radiol. 2011;21:1948–55.CrossRefGoogle Scholar
  6. 6.
    Grimm IS, Baron TH. Biliary stents for palliation of obstructive jaundice: choosing the superior endoscopic management strategy. Gastroenterology. 2015;149:20–2.CrossRefGoogle Scholar
  7. 7.
    Li SY, Kim CW, Jeon UB, et al. Early infectious complications of percutaneous metallic stent insertion for malignant biliary obstruction. Am J Roentgenol. 2010;194:261–5.CrossRefGoogle Scholar
  8. 8.
    Jo JH, Park BH. Suprapapillary versus transpapillary stent placement for malignant biliary obstruction: which is better. J Vasc Interv Radiol. 2015;26:573–82.CrossRefGoogle Scholar
  9. 9.
    Huang X, Shen L, Jin Y, et al. Comparison of uncovered stent placement across versus above the main duodenal papilla for malignant biliary obstruction. J Vasc Interv Radiol. 2015;26:432–7.CrossRefGoogle Scholar
  10. 10.
    Togawa O, Isayama H, Tsujino T, et al. Management of dysfunctional covered self-expandable metallic stents in patients with malignant distal biliary obstruction. J Gastroenterol. 2013;48:1300–7.CrossRefGoogle Scholar
  11. 11.
    Li J, Li T, Sun P, et al. Covered versus uncovered self-expandable metal stents for managing malignant distal biliary obstruction: a meta-analysis. PLoS ONE. 2016;11:e0149066.CrossRefGoogle Scholar
  12. 12.
    Kim JY, Ko GB, Lee TH, et al. Partially covered metal stents may not prolong stent patency compared to uncovered stents in unresectable malignant distal biliary obstruction. Gut Liver. 2017;11:440–6.CrossRefGoogle Scholar
  13. 13.
    Boeckel PGV, Vleggaar FP, Steyerberg EW, et al. Factors predicting patency of stents placed for malignant biliary strictures: a cox regression analysis. Gastrointest Endosc. 2009;69:153–4.CrossRefGoogle Scholar
  14. 14.
    Miura S, Kanno A, Masamune A, et al. Risk factors for recurrent biliary obstruction following placement of self-expandable metallic stents in patients with malignant perihilar biliary stricture. Endoscopy. 2016;48:536–45.CrossRefGoogle Scholar
  15. 15.
    Eum YO, Kim YT, Lee SH, et al. Stent patency using competing risk model in unresectable pancreatic cancers inserted with biliary self-expandable metallic stent. Dig Endosc. 2013;25:67–75.CrossRefGoogle Scholar
  16. 16.
    Hamada T, Isayama H, Nakai Y, et al. Duodenal invasion is a risk factor for the early dysfunction of biliary metal stents in unresectable pancreatic cancer. Gastrointest Endosc. 2011;74:548–55.CrossRefGoogle Scholar
  17. 17.
    Nakai Y, Isayama H, Kogure H, et al. Risk factors for covered metallic stent migration in patients with distal malignant biliary obstruction due to pancreatic cancer. J Gastroen Hepatol. 2014;29:1744–9.CrossRefGoogle Scholar
  18. 18.
    Hamada T, Nakai Y, Isayama H, et al. Competing risk: a potential risk factor for misleading results of length of stent patency. Endoscopy. 2013;45:72 (Author reply).CrossRefGoogle Scholar
  19. 19.
    Koller MT, Raatz H, Steyerberg EW, et al. Competing risks and the clinical community: irrelevance or ignorance? Stat Med. 2012;31:1089–97.CrossRefGoogle Scholar
  20. 20.
    Austin PC, Fine JP. Accounting for competing risks in randomized controlled trials: a review and recommendations for improvement. Stat Med. 2017;36:1203–9.CrossRefGoogle Scholar
  21. 21.
    Leffondré K, Touraine C, Helmer C, et al. Interval-censored time-to-event and competing risk with death: is the illness-death model more accurate than the Cox model? Int J Epidemiol. 2013;42:1177–86.CrossRefGoogle Scholar
  22. 22.
    Isayama H, Hamada T, Yasuda I, et al. TOKYO criteria 2014 for transpapillary biliary stenting. Dig Endosc. 2015;27:259–64.CrossRefGoogle Scholar
  23. 23.
    van Boeckel PG, Steyerberg EW, Vleggaar FP, et al. Multicenter study evaluating factors for stent patency in patients with malignant biliary strictures: development of a simple score model. J Gastroenterol. 2011;46:1104–10.CrossRefGoogle Scholar
  24. 24.
    Nakai Y, Isayama H, Mukai T, et al. Impact of anticancer treatment on recurrent obstruction in covered metallic stents for malignant biliary obstruction. J Gastroenterol. 2013;48:1293–9.CrossRefGoogle Scholar
  25. 25.
    Li M, Li K, Qi X, et al. Percutaneous transhepatic biliary stent implantation for obstructive jaundice of perihilar cholangiocarcinoma: a prospective study on predictors of stent patency and survival in 92 patients. J Vasc Interv Radiol. 2016;27:1047–55.CrossRefGoogle Scholar
  26. 26.
    Woo SM, Ryu JK, Lee SH, et al. Recurrence and prognostic factors of ampullary carcinoma after radical resection: comparison with distal extrahepatic cholangiocarcinoma. Ann Surg Oncol. 2007;14:3195–201.CrossRefGoogle Scholar
  27. 27.
    Hatzaras I, George N, Muscarella P, et al. Predictors of survival in periampullary cancers following pancreaticoduodenectomy. Ann Surg Oncol. 2010;17:991–7.CrossRefGoogle Scholar
  28. 28.
    Su BP, Kim HW, Kang DH, et al. Metallic or plastic stent for bile duct obstruction in ampullary cancer? Dig Dis Sci. 2012;57:786–90.CrossRefGoogle Scholar
  29. 29.
    Dumonceau JM, Tringali A, Blero D, et al. Biliary stenting: indications, choice of stents and results: European Society of Gastrointestinal Endoscopy (ESGE) clinical guideline. Endoscopy. 2012;44:277–98.CrossRefGoogle Scholar
  30. 30.
    Kitano M, Yamashita Y, Tanaka K, et al. Covered self-expandable metal stents with an anti-migration system improve patency duration without increased complications compared with uncovered stents for distal biliary obstruction caused by pancreatic carcinoma: a randomized multicenter trial. Am J Gastroenterol. 2013;108:1713–22.CrossRefGoogle Scholar
  31. 31.
    Cho JN, Han J, Kim HG, et al. Prospective randomized trial comparing covered metal stent placed above and across the sphincter of oddi in malignant biliary obstruction. Gastrointest Endosc. 2013;77:139–40.Google Scholar
  32. 32.
    Lee DH, Yu JS, Hwang JC, et al. Percutaneous placement of self-expandable metallic biliary stents in malignant extrahepatic strictures: indications of transpapillary and suprapapillary methods. Korean J Radiol. 2000;1:65–72.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2018

Authors and Affiliations

  1. 1.Department of Interventional RadiologyThe First Affiliated Hospital with Nanjing Medical UniversityNanjingChina

Personalised recommendations